Willy A Flegel1, Jerome L Gottschall2,3, Gregory A Denomme3. 1. Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland. 2. Department of Pathology, Medical College of Wisconsin. 3. Diagnostic Laboratories, BloodCenter of Wisconsin, Milwaukee, Wisconsin.
Abstract
BACKGROUND: When problems with compatibility beyond ABO and D arise, currently transfusion services search their inventories and perform time-consuming serologic testing to locate antigen-negative blood. These clinically important blood group antigens can be detected reliably by red cell genotyping, which is a technology whereby DNA-based techniques are used to evaluate gene polymorphisms that determine the expression of blood group antigens. We introduced mass-scale genotyping and measured availability of genotyped blood. STUDY DESIGN AND METHODS: All non-Caucasian donors qualified for genotyping along with donors who had a history of repeat donation. Mass-scale red cell genotyping, performed on an electronic interfaced open array platform, was implemented to screen blood donors for 32 single-nucleotide polymorphisms that predicted 42 blood group antigens. Genotype screening results were confirmed by phenotyping, when needed for antigen-negative transfusion, before release of the red blood cell (RBC) unit. RESULTS: Approximately 22,000 donors were red cell genotyped within 4 months and a total of 43,066 donors in 4 years. There were 463 discordances (0.52% of 89,596 genotypes with a phenotype). Among the 307 resolved discordances, approximate equal numbers represented historical serologic or genotyping discrepancies (n = 151 and n = 156, respectively). In the final year of the study, a mean of 29% of the daily inventory had a genotype. CONCLUSIONS: Red cell genotyping of blood donors using an electronic interface created a large and stable supply of RBC units with historical genotypes. The database served the needs of antigen-negative blood requests for a large regional blood center and allowed us to abandon screening by serology.
BACKGROUND: When problems with compatibility beyond ABO and D arise, currently transfusion services search their inventories and perform time-consuming serologic testing to locate antigen-negative blood. These clinically important blood group antigens can be detected reliably by red cell genotyping, which is a technology whereby DNA-based techniques are used to evaluate gene polymorphisms that determine the expression of blood group antigens. We introduced mass-scale genotyping and measured availability of genotyped blood. STUDY DESIGN AND METHODS: All non-Caucasian donors qualified for genotyping along with donors who had a history of repeat donation. Mass-scale red cell genotyping, performed on an electronic interfaced open array platform, was implemented to screen blood donors for 32 single-nucleotide polymorphisms that predicted 42 blood group antigens. Genotype screening results were confirmed by phenotyping, when needed for antigen-negative transfusion, before release of the red blood cell (RBC) unit. RESULTS: Approximately 22,000 donors were red cell genotyped within 4 months and a total of 43,066 donors in 4 years. There were 463 discordances (0.52% of 89,596 genotypes with a phenotype). Among the 307 resolved discordances, approximate equal numbers represented historical serologic or genotyping discrepancies (n = 151 and n = 156, respectively). In the final year of the study, a mean of 29% of the daily inventory had a genotype. CONCLUSIONS: Red cell genotyping of blood donors using an electronic interface created a large and stable supply of RBC units with historical genotypes. The database served the needs of antigen-negative blood requests for a large regional blood center and allowed us to abandon screening by serology.
Authors: Poonsub Palacajornsuk; Christine Halter; Victoria Isakova; Michal Tarnawski; James Farmar; Marion E Reid; Asok Chaudhuri Journal: Transfusion Date: 2009-01-02 Impact factor: 3.157
Authors: Neil D Avent; Antonio Martinez; Willy A Flegel; Martin L Olsson; Marion L Scott; Núria Nogués; Martin Písăcka; Geoff L Daniels; Eduardo Muñiz-Diaz; Tracey E Madgett; Jill R Storry; Sigrid Beiboer; Petra M Maaskant-van Wijk; Inge von Zabern; Elisa Jiménez; Diego Tejedor; Monica López; Emma Camacho; Goedele Cheroutre; Anita Hacker; Pavel Jinoch; Irena Svobodova; Ellen van der Schoot; Masja de Haas Journal: Transfus Med Hemother Date: 2009-05-28 Impact factor: 3.747
Authors: Franz F Wagner; Rita Bittner; Eduard K Petershofen; Andrea Doescher; Thomas H Müller Journal: Transfusion Date: 2008-04-15 Impact factor: 3.157
Authors: G L Daniels; B H Faas; C A Green; E Smart; P A Maaskant-van Wijk; N D Avent; H A Zondervan; A E von dem Borne; C E van der Schoot Journal: Transfusion Date: 1998-10 Impact factor: 3.157
Authors: Willy A Flegel; Lilian Castilho; Wm Andrew L Heaton; Margaret A Keller; Ellen B Klapper; William J Lane; France Pirenne; Nadine Shehata; Gary Stack; Maryse St-Louis; Christopher A Tormey; Franz F Wagner; Dan A Waxman; Gregory A Denomme Journal: Blood Transfus Date: 2016-07-29 Impact factor: 3.443
Authors: Gregory A Denomme; Waseem Q Anani; Neil D Avent; Gregor Bein; Lynne B Briggs; Razvan C Lapadat; Celina Montemayor; Maria Rios; Maryse St-Louis; Lynne Uhl; Silvano Wendel; Willy A Flegel Journal: Ther Adv Hematol Date: 2017-09-13